Clinical Trial

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting
View on ClinicalTrials.gov →
Summary
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD indexes of Senl-T7 were collected.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-15.
Trial Details
NCT Number NCT05626400
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Conditions T-cell Acute Lymphoblastic Leukemia/Lymphoma
Enrollment 100 participants
Start Date 2022-08-29
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2022-11-25